Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for...
FDA Drug Recall #D-324-2013 — Class I — January 31, 2013
Recall Summary
| Recall Number | D-324-2013 |
| Classification | Class I — Serious risk |
| Date Initiated | January 31, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Gilead Sciences, Inc. |
| Location | Foster City, CA |
| Product Type | Drugs |
| Quantity | 3,181 vials |
Product Description
Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.
Reason for Recall
Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).
Distribution Pattern
Nationwide in USA, Canada, and UK (Gilead facility in Cork Ireland). Cork facility distributed to Germany/Austria, Italy and Spain.
Lot / Code Information
Lot #: B120217A, Exp 05/15 - US Distribution
Other Recalls from Gilead Sciences, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0005-2025 | Class I | Veklury (remdesivir) for injection, 100 mg/vial... | Sep 19, 2024 |
| D-0299-2022 | Class I | Veklury (remdesivir) for injection, 100 mg/vial... | Dec 3, 2021 |
| D-0045-2015 | Class II | Emtriva (emtricitabine) Oral Solution, 10 mg/mL... | Oct 1, 2014 |
| D-0013-2015 | Class III | Truvada (200 mg emtricitabine and 300 mg tenofo... | Sep 30, 2014 |
| D-1090-2014 | Class III | Atripla (efavirenz 600 mg/ emtricitabine 200 mg... | Feb 19, 2014 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.